PerkinElmer
check quantity

PCSK9 (human) LANCE Ultra TR-FRET Detection Kit, 500 Assay Points

The LANCE® Ultra Human PCSK9 Detection Kit is designed for detection and quantitation of human Proprotein Convertase Subtilisin/Kexin Type 9 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

项目已成功添加到购物车

For research use only. Not for use in diagnostic procedures.

部件号
产品尺寸
TRF1270C
500 Assay Points
更多
TRF1270M
10,000 Assay Points
更多
立即购买

请输入有效的数量

请登录后再添加至收藏夹

购物车为空

詳情 信息

The LANCE Ultra Human PCSK9 Detection Kit is designed for detection and quantitation of human PCSK9 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

  • No-wash steps, no separation steps
  • TR-FRET technology
  • Sensitive detection
  • High reproducibility
  • Faster time-to-results
  • Easy automation
  • 96-well, 384-well, and 1536-well formats
 

LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) belongs to the proteinase K subfamily of the secretory subtilase family. This glycoprotein contains 692 amino acids, including a signal peptide, a prodomain, and a catalytic domain. Initially synthesized as a soluble 74 kDa precursor protein, it is cleaved into 14 kDa and 60 kDa domains, which remain associated. This protein plays a major regulatory role in cholesterol homeostasis and is highly expressed in the kidney, liver, and intestine. PCSK9 binds to the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoprotein, which could lead to hypercholesterolemia. Inhibition of PCSK9 function is currently being explored as a means of lowering cholesterol levels. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia.

规格

检测目标 PCSK9
检测目标类 Protein
运输条件 蓝冰
治疗领域 Metabolic
产品尺寸 500 Assay Points